Literature DB >> 6541533

Improved control of cisplatin-induced emesis with a metoclopramide-dexamethasone combination.

F Cognetti, P Pinnaro, P Carlini, C Caporali, E M Ruggeri, C F Pollera.   

Abstract

Twenty-four patients receiving combination chemotherapy including cisplatin at a dosage of 50 mg/m2 were entered on this antiemetic randomized open cross-over study. High-dose dexamethasone (DXM) (regimen A) was compared with the combination of DXM and high doses of metoclopramide (MCP) (regimen B). Five patients (20%) treated with regimen A and 13 (54%) treated with regimen B suffered neither nausea nor vomiting (P less than 0.05). Regimen B was found to be significantly more effective than regimen A for all the parameters of evaluation considered. No severe side-effects were observed.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6541533     DOI： 10.1007/bf00269037

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  9 in total

1.  Antiemetics: neurotransmitter receptor binding predicts therapeutic actions.

Authors:  S J Peroutka; S H Snyder
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

2.  The role of prostaglandins in the excessive nausea and vomiting after intravascular cis-platinum therapy.

Authors:  S L Curry; J Rine; C W Whitney; W A Nahhas; R Mortel; L M Demers
Journal:  Gynecol Oncol       Date:  1981-08       Impact factor: 5.482

3.  Study design for the evaluation of the efficacy and safety of nabilone.

Authors:  P Stark
Journal:  Cancer Treat Rev       Date:  1982-12       Impact factor: 12.111

4.  High-dose dexamethasone for prevention of cis-platin-induced vomiting.

Authors:  M S Aapro; D S Alberts
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting.

Authors:  F Cognetti; P Pinnarò; P Carlini; E M Conti; M Cortese; C F Pollera
Journal:  Eur J Cancer Clin Oncol       Date:  1984-02

6.  Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide.

Authors:  J A Neidhart; M Gagen; D Young; H E Wilson
Journal:  Cancer       Date:  1981-03-15       Impact factor: 6.860

7.  Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide.

Authors:  E D Bruera; E Roca; L Cedaro; R Chacón; R Estévez
Journal:  Cancer Treat Rep       Date:  1983-04

Review 8.  The control of chemotherapy-induced emesis.

Authors:  L J Seigel; D L Longo
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391

9.  Toxicity of cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration.

Authors:  S E Vogl; T Zaravinos; B H Kaplan
Journal:  Cancer       Date:  1980-01-01       Impact factor: 6.860
  9 in total
  2 in total

Review 1.  Standard treatment of chemotherapy-induced emesis.

Authors:  D Warr
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

2.  A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin.

Authors:  C F Pollera; M Nardi; P Marolla; P Carlini
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.